Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

From genetic testing to prevention: an integrated clinical pathway for hereditary risk assessment in tubo-ovarian cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society - 1 Sept 2026

Viveros-Carreño David, Mora-Soto Nathalia, Beshar Isabel, Agustí Nuria, Martínez-Cruz Lucía, Fernandes Andreina, Buda Alessandro, Rauh-Hain Alejandro, Pareja René

Abstract excerpt

Hereditary tubo-ovarian cancer risk assessment has evolved from a BRCA1/2-centered consultation to an integrated prevention pathway that begins at diagnosis and extends to unaffected relatives. Germline testing is now justified for patients with epithelial tubo-ovarian cancer because actionable pathogenic variants are common enough that family-history-only referral misses many carriers. The central clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Ovarian cancer diagnosis and treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to PARP inhibition in cancer therapy

Source

Identifiers

PMID: 42617415
DOI: 10.1016/j.ijgc.2026.104898

Genes

BRCA1
BRCA2
BRIP1
PALB2
RAD51C
RAD51D

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

From genetic testing to prevention: an integrated clinical pathway for hereditary risk assessment in tubo-ovarian cancer.PMID 42617415Read ↗

Contemporary risk assessment and risk-reducing strategies for tubo-ovarian cancer in women with BRCA pathogenic variants.Semantic proximity Read ↗

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.Semantic proximity Read ↗

Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.Semantic proximity Read ↗

Genetic risk assessment in breast and gynecologic malignancies- what's to know in 2024?Semantic proximity Read ↗

Cancer Genetic Predisposition and Clinical Applications-A Narrative Review on Germline Genetic Testing, High-Risk Cancer Surveillance and Management.Semantic proximity Read ↗

Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes.Semantic proximity Read ↗

NSGC Practice Guideline: Risk Assessment and Genetic Counseling for Hereditary Breast and Ovarian CancerSemantic proximity Read ↗

Genetic counseling, testing, and screening for breast and ovarian cancer: practical and social considerations.Semantic proximity Read ↗

Genetic Cancer: From Hereditary Risk to Precision OncologySemantic proximity Read ↗

Genetic Cancer: From Hereditary Risk to Precision OncologySemantic proximity Read ↗

Hereditary Breast and Ovarian Cancer: An Updated Primer for OB/GYNs.Semantic proximity Read ↗

Hereditary gynecologic cancers: risk assessment, counseling, testing and management.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.